Clinical Strategizing of PARP Inhibitors in Castration Resistant Prostate Cancer

Novel Approaches and New Therapeutic Platforms

Ludmil Alexandrov (UCSD)

Rana McKay (UCSD)

Prostate cancer is the most common cancer diagnosis in men. With more than 160,000 new cases each year in the United States, it remains the second-leading cause of male cancer death in the US. This collaborative bench-to-bed project will use next-generation sequencing to increase the precision and effectiveness of therapy for patients. By integrating state-of-the-art bioinformatic and genomic analysis of patients enrolled in Phase 2 trials, this project expects to significantly improve outcomes by providing molecular-tailored treatments for individuals with this disease.